Integrated FHIT and IDH2 biomarker profiling predicts lethal sensitivity to DCPS inhibition in Acute Myeloid Leukemia and Myelodysplastic syndrome

Abstract Background/objectives Development of novel therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) is hindered by limited biomarkers to identify appropriate target populations and poor translatability of preclinical drug candidates. In this study, we sought to validate...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Francesca Grassi, Lisa Bast, Madhurendra Singh, Magnus Tobiasson, Julian Walfridsson, Angelo de Milito, Martin Andersson, Andreas Höglund
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Springer 2026-03-01
Saila:	Discover Oncology
Sarrera elektronikoa:	https://doi.org/10.1007/s12672-026-04880-x
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!